EUCTR2020-004628-40-FRActive, not recruitingPhase 1
Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. - Maralixibat Infant Safety Evaluation (RISE).
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Mirum Pharmaceuticals Inc
- Enrollment
- 12
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Informed consent (by the legally authorized representative) per the Institutional Review Board/Ethics Committee
- •2. Body weight of =2.5 kg
- •3. =31 days and <12 months of age at the baseline visit (At least 3 participants in each cohort must be <9 months of age at the baseline visit)
- •4. Gestational age =36 weeks at birth
- •5. Diagnosis of PFIC or ALGS based on the following:
- •PFIC: Participants with genetic testing results consistent with at least one disease-causing mutation associated with PFIC alongside clinical or biochemical evidence of cholestasis
- •ALGS: Participants meeting the ALGS diagnostic criteria outlined in the protocol alongside clinical or biochemical evidence of cholestasis
- •6. Caregiver willingness to comply with all study visits and requirements, including ability to read and understand the questionnaires and, if applicable, capable of diluting maralixibat per investigator training and written instructions
- •7. Caregiver access to email or phone for remote participant contacts.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. History of surgical disruption of the enterohepatic circulation.
- •2. Chronic diarrhea requiring ongoing intravenous fluid or nutritional intervention at screening, during the screening period, or during the 30 days prior to screening
- •3. History of liver transplant or imminent need for liver transplant
- •4. Decompensated cirrhosis (international normalized ratio >1.5 despite vitamin K supplementation, albumin <30 g/L, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy)
- •5. ALT or TSB > 15× the upper limit of normal at screening
- •6. Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease), per investigator discretion
- •7. Presence of other significant liver disease or any other conditions or abnormalities which, in the opinion of the investigator or medical monitor, may compromise the safety of the participant or interfere with the participant’s participation in or completion of the study
- •8. Liver mass on imaging, including screening ultrasound, suspected to be hepatocellular carcinoma
- •9. Receipt of investigational drug, biologic, or medical device within 30 days or 5 half-lives (whichever is longer) prior to screening
- •10. Previous treatment with an ASBT inhibitor
- •11. Known hypersensitivity to maralixibat or any of its excipients
- •12. Known caregiver history of unreliability, mental instability, or cognitive impairment that, in the opinion of the investigator or medical monitor, could compromise the validity of informed consent, compromise the safety of the participant, or lead to nonadherence with the study protocol or inability to conduct the study procedures.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Clinical study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome.Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome.MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10053870Term: Alagille syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004628-40-PLMirum Pharmaceuticals Inc27
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Effect of three drugs ABT-450, ABT-267 and ABT-333 with Ritonavir and sometimes with Ribavirin in people who have had a Transplant and have Hepatitis C Virus (HCV) infection.Chronic Hepatitis C InfectionMedDRA version: 20.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2012-004792-39-GBAbbVie Deutschland GmbH & Co. KG129
Active, not recruiting
Phase 1
Clinical study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome.Progressive Familial Intrahepatic Cholestasis and Alagille SyndromeMedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10053870Term: Alagille syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004628-40-BEMirum Pharmaceuticals Inc27
Recruiting
Phase 1
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BEMNIFOSBUVIR AND RUZASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTIOChronic Hepatitis C Virus (HCV) InfectionMedDRA version: 20.1Level: PTClassification code: 10008912Term: Chronic hepatitis C Class: 100000004862CTIS2023-504566-28-00Atea Pharmaceuticals Inc.249
Active, not recruiting
Phase 1
Study to evaluate the safety and efficacy of APX001 in the treatment of patients with invasive mold infectionsEUCTR2019-001386-33-BEAmplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer, Inc.50